{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "K",
          "alt": "N",
          "position": "27"
        },
        "variant_string_id": "PARK2 K27N"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal recessive juvenile Parkinsonism (AR-JP) is directly linked to mutations in the parkin gene, and pathogenic mutations in the Ubl domain disrupt autoinhibition, leading to constitutive activation of Parkin autoubiquitination.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a disruption of Parkin autoinhibition due to mutations in the Ubl domain, resulting in increased autoubiquitination activity, which is implicated in AR-JP."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro autoubiquitination assays were used to assess Parkin activity, comparing wild-type (WT) and mutant forms, showing that pathogenic mutations like K27N relieve autoinhibition.",
          "judgment": "Yes",
          "reasoning": "Autoubiquitination assays are a relevant class of assay for studying E3 ligase activity and directly reflect the disease mechanism of disrupted autoinhibition in Parkinson’s disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type Parkin was used as a negative control (inactive for autoubiquitination), and DUbl-Parkin (lacking Ubl domain) as a positive control (constitutively active). Experiments were performed multiple times, though exact replicate numbers are not specified for each variant.",
          "judgment": "No",
          "reasoning": "While both normal (WT) and abnormal (DUbl-Parkin) controls are included, the paper does not explicitly state the use of multiple replicates for each specific variant assay, failing to meet both conditions fully.",
          "next_step_or_outcome": "Proceed to Step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "Autoubiquitination assays are adapted from Matsuda et al. (2006), indicating prior use and validation in the field for studying Parkin activity.",
          "judgment": "Yes",
          "reasoning": "The assay is based on a previously validated method cited in the literature, meeting the condition for historical acceptance or prior validation.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 K27N supports pathogenicity at a supporting level (PS3_supporting) due to the use of a validated autoubiquitination assay demonstrating relief of autoinhibition, despite lacking explicit replicate data or variant-specific controls."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "Q",
          "position": "33"
        },
        "variant_string_id": "PARK2 R33Q"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal recessive juvenile Parkinsonism (AR-JP) is directly linked to mutations in the parkin gene, and pathogenic mutations in the Ubl domain disrupt autoinhibition, leading to constitutive activation of Parkin autoubiquitination.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a disruption of Parkin autoinhibition due to mutations in the Ubl domain, resulting in increased autoubiquitination activity, which is implicated in AR-JP."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro autoubiquitination assays were used to assess Parkin activity, comparing wild-type (WT) and mutant forms, showing that pathogenic mutations like R33Q relieve autoinhibition.",
          "judgment": "Yes",
          "reasoning": "Autoubiquitination assays are a relevant class of assay for studying E3 ligase activity and directly reflect the disease mechanism of disrupted autoinhibition in Parkinson’s disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type Parkin was used as a negative control (inactive for autoubiquitination), and DUbl-Parkin as a positive control (constitutively active). Experiments were performed multiple times, though exact replicate numbers are not specified for each variant.",
          "judgment": "No",
          "reasoning": "While both normal (WT) and abnormal (DUbl-Parkin) controls are included, the paper does not explicitly state the use of multiple replicates for each specific variant assay, failing to meet both conditions fully.",
          "next_step_or_outcome": "Proceed to Step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "Autoubiquitination assays are adapted from Matsuda et al. (2006), indicating prior use and validation in the field for studying Parkin activity.",
          "judgment": "Yes",
          "reasoning": "The assay is based on a previously validated method cited in the literature, meeting the condition for historical acceptance or prior validation.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 R33Q supports pathogenicity at a supporting level (PS3_supporting) due to the use of a validated autoubiquitination assay demonstrating relief of autoinhibition, despite lacking explicit replicate data or variant-specific controls."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "P",
          "position": "42"
        },
        "variant_string_id": "PARK2 R42P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal recessive juvenile Parkinsonism (AR-JP) is directly linked to mutations in the parkin gene, and pathogenic mutations in the Ubl domain disrupt autoinhibition, leading to constitutive activation of Parkin autoubiquitination.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a disruption of Parkin autoinhibition due to mutations in the Ubl domain, resulting in increased autoubiquitination activity, which is implicated in AR-JP."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro autoubiquitination assays were used to assess Parkin activity, comparing wild-type (WT) and mutant forms, showing that pathogenic mutations like R42P relieve autoinhibition.",
          "judgment": "Yes",
          "reasoning": "Autoubiquitination assays are a relevant class of assay for studying E3 ligase activity and directly reflect the disease mechanism of disrupted autoinhibition in Parkinson’s disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type Parkin was used as a negative control (inactive for autoubiquitination), and DUbl-Parkin as a positive control (constitutively active). Experiments were performed multiple times, though exact replicate numbers are not specified for each variant.",
          "judgment": "No",
          "reasoning": "While both normal (WT) and abnormal (DUbl-Parkin) controls are included, the paper does not explicitly state the use of multiple replicates for each specific variant assay, failing to meet both conditions fully.",
          "next_step_or_outcome": "Proceed to Step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "Autoubiquitination assays are adapted from Matsuda et al. (2006), indicating prior use and validation in the field for studying Parkin activity.",
          "judgment": "Yes",
          "reasoning": "The assay is based on a previously validated method cited in the literature, meeting the condition for historical acceptance or prior validation.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 R42P supports pathogenicity at a supporting level (PS3_supporting) due to the use of a validated autoubiquitination assay demonstrating relief of autoinhibition, despite lacking explicit replicate data or variant-specific controls."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "46"
        },
        "variant_string_id": "PARK2 A46P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal recessive juvenile Parkinsonism (AR-JP) is directly linked to mutations in the parkin gene, and pathogenic mutations in the Ubl domain disrupt autoinhibition, leading to constitutive activation of Parkin autoubiquitination.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a disruption of Parkin autoinhibition due to mutations in the Ubl domain, resulting in increased autoubiquitination activity, which is implicated in AR-JP."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro autoubiquitination assays were used to assess Parkin activity, comparing wild-type (WT) and mutant forms, showing that pathogenic mutations like A46P relieve autoinhibition.",
          "judgment": "Yes",
          "reasoning": "Autoubiquitination assays are a relevant class of assay for studying E3 ligase activity and directly reflect the disease mechanism of disrupted autoinhibition in Parkinson’s disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type Parkin was used as a negative control (inactive for autoubiquitination), and DUbl-Parkin as a positive control (constitutively active). Experiments were performed multiple times, though exact replicate numbers are not specified for each variant.",
          "judgment": "No",
          "reasoning": "While both normal (WT) and abnormal (DUbl-Parkin) controls are included, the paper does not explicitly state the use of multiple replicates for each specific variant assay, failing to meet both conditions fully.",
          "next_step_or_outcome": "Proceed to Step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "Autoubiquitination assays are adapted from Matsuda et al. (2006), indicating prior use and validation in the field for studying Parkin activity.",
          "judgment": "Yes",
          "reasoning": "The assay is based on a previously validated method cited in the literature, meeting the condition for historical acceptance or prior validation.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 A46P supports pathogenicity at a supporting level (PS3_supporting) due to the use of a validated autoubiquitination assay demonstrating relief of autoinhibition, despite lacking explicit replicate data or variant-specific controls."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "K",
          "alt": "A",
          "position": "48"
        },
        "variant_string_id": "PARK2 K48A"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal recessive juvenile Parkinsonism (AR-JP) is directly linked to mutations in the parkin gene, and pathogenic mutations in the Ubl domain disrupt autoinhibition, leading to constitutive activation of Parkin autoubiquitination.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a disruption of Parkin autoinhibition due to mutations in the Ubl domain, resulting in increased autoubiquitination activity, which is implicated in AR-JP."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro autoubiquitination assays were used to assess Parkin activity, comparing wild-type (WT) and mutant forms, showing that mutations like K48A relieve autoinhibition.",
          "judgment": "Yes",
          "reasoning": "Autoubiquitination assays are a relevant class of assay for studying E3 ligase activity and directly reflect the disease mechanism of disrupted autoinhibition in Parkinson’s disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type Parkin was used as a negative control (inactive for autoubiquitination), and DUbl-Parkin as a positive control (constitutively active). Experiments were performed multiple times, though exact replicate numbers are not specified for each variant.",
          "judgment": "No",
          "reasoning": "While both normal (WT) and abnormal (DUbl-Parkin) controls are included, the paper does not explicitly state the use of multiple replicates for each specific variant assay, failing to meet both conditions fully.",
          "next_step_or_outcome": "Proceed to Step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "Autoubiquitination assays are adapted from Matsuda et al. (2006), indicating prior use and validation in the field for studying Parkin activity.",
          "judgment": "Yes",
          "reasoning": "The assay is based on a previously validated method cited in the literature, meeting the condition for historical acceptance or prior validation.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 K48A supports pathogenicity at a supporting level (PS3_supporting) due to the use of a validated autoubiquitination assay demonstrating relief of autoinhibition, despite lacking explicit replicate data or variant-specific controls."
    }
  ]
}